Acadian Asset Management LLC raised its stake in shares of Rigel Pharmaceuticals, Inc. () by 23.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.

Source: https://www.dailypolitical.com/2023/11/10/acadian-asset-management-llc-has-5-91-million-stock-position-in-rigel-pharmaceuticals-inc-nasdaqrigl.html

ACADIA Pharmaceuticals has a twelve month low of $13.73 and a twelve month high of $32.89.

Source: https://www.americanbankingnews.com/2023/07/15/acadia-pharmaceuticals-nasdaqacad-given-new-33-00-price-target-at-hc-wainwright.html

Acadia's recent increased spending on milestones and operational costs for Daybue's launch, along with its expanded partnership with Neuren Pharmaceuticals, showcases a deep commitment to the neurological sector.

Source: https://seekingalpha.com/article/4657086-acadias-daybue-a-small-patient-pool-making-big-waves?source=feed_all_articles

According to data from MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $32.

Source: https://www.etfdailynews.com/2023/12/15/eyepoint-pharmaceuticals-nasdaqeypt-now-covered-by-analysts-at-capital-one-financial/

AcelRx Pharmaceuticals has a 12-month low of $1.65 and a 12-month high of $9.60.

Source: https://www.etfdailynews.com/2023/02/14/acelrx-pharmaceuticals-inc-nasdaqacrx-sees-large-drop-in-short-interest/

A dosing cup, syringe and bottle of the drug Xyrem, produced by Jazz Pharmaceuticals.

Source: https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html

Advisors Asset Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 94.6% during the first quarter.

Source: https://www.etfdailynews.com/2023/04/29/arrowhead-pharmaceuticals-inc-nasdaqarwr-stock-position-lifted-by-zurcher-kantonalbank-zurich-cantonalbank/

Alliancebernstein L.P. increased its stake in Amylyx Pharmaceuticals by 1.0% during the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/11/12/amylyx-pharmaceuticals-nasdaqamlx-pt-lowered-to-40-00-at-the-goldman-sachs-group.html

Allianz Asset Management GmbH lessened its stake in Ionis Pharmaceuticals, Inc. () by 99.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC.

Source: https://www.etfdailynews.com/2023/02/17/allianz-asset-management-gmbh-decreases-stock-position-in-ionis-pharmaceuticals-inc-nasdaqions/

Allspring Global Investments Holdings LLC trimmed its position in shares of Tarsus Pharmaceuticals, Inc. () by 9.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

Source: https://www.etfdailynews.com/2023/01/27/allspring-global-investments-holdings-llc-cuts-stock-holdings-in-tarsus-pharmaceuticals-inc-nasdaqtars/

Alnylam Pharmaceuticals ): The pharma company has six commercial products, three of which received a breakthrough designation.

Source: https://investorplace.com/2023/03/3-growth-stocks-that-could-disrupt-the-healthcare-industry/

Also, CFO Robert E. Landry sold 739 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 3rd.

Source: https://www.etfdailynews.com/2023/04/08/park-avenue-securities-llc-buys-64-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn/

Amalgamated Bank boosted its stake in Alnylam Pharmaceuticals, Inc. () by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.

Source: https://www.americanbankingnews.com/2023/06/03/amalgamated-bank-buys-387-shares-of-alnylam-pharmaceuticals-inc-nasdaqalny.html

Amalgamated Bank raised its stake in Enanta Pharmaceuticals by 4.7% in the third quarter.

Source: https://www.etfdailynews.com/2023/05/25/citigroup-inc-reduces-position-in-enanta-pharmaceuticals-inc-nasdaqenta/

Amgen is in the hunt with olpasiran, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that has reached late-stage clinical development.

Source: https://medcitynews.com/2023/06/eli-lilly-cardiovascular-disease-in-vivo-gene-editing/

Amneal Pharmaceuticals, Inc. has a 1-year low of $1.24 and a 1-year high of $4.74.

Source: https://www.etfdailynews.com/2023/08/26/connor-clark-lunn-investment-management-ltd-boosts-stock-position-in-amneal-pharmaceuticals-inc-nyseamrx/

Amneal Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $4.98.

Source: https://www.etfdailynews.com/2023/02/10/amneal-pharmaceuticals-inc-nyseamrx-shares-purchased-by-prudential-financial-inc/

Amphastar Pharmaceuticals has implemented aggressive corporate strategies to maximize margins and increase sales, resulting in impressive EBIT and revenue growth.

Source: https://seekingalpha.com/article/4640072-amphastar-pharmaceuticals-great-growth-at-a-high-price?source=feed_all_articles

Amphastar Pharmaceuticals, Inc. has a 12-month low of $26.76 and a 12-month high of $67.66.

Source: https://www.etfdailynews.com/2023/08/13/amphastar-pharmaceuticals-inc-nasdaqamph-shares-sold-by-oregon-public-employees-retirement-fund/

Amphastar Pharmaceuticals () last posted its quarterly earnings data on Tuesday, August 8th.

Source: https://www.americanbankingnews.com/2023/08/30/california-state-teachers-retirement-system-cuts-stock-position-in-amphastar-pharmaceuticals-inc-nasdaqamph.html